Health Condition 1: K039- Disease of hard tissues of teeth,unspecified
Conditions
Interventions
Intervention1: Recombinant Bone morphogenetic proteins (rh-BMP: Recombinant human bone morphogenetic protein (rhBMP) is a breakthrough in regenerative medicine because of its strong osteoinductive pot
Sponsors
Pravra Institute Of Medical Sciences loni Ahilyanagar Maharashtra IndiaPin
Eligibility
Inclusion criteria
Inclusion criteria: Patients ready to give informed consent. Patients with no systemic disease. Patients with chronic periodontitis. The patients should have an ability to maintain good oral hygiene. The patients must give an informed consent for the surgical procedure. Patient with bilateral radiographic evidence of vertical bone loss. Patients with moderate to severe periodontitis with intrabony 3 wall defect treated with open flap debridement and only allograft alone on either side of dental Patient having a minimum 20 Permanent teeth with at-least 2 teeth having three walled intra-bony defects (IBD) more than or equal to 4 mm deep [distance between alveolar crest and base of the defect as detected on intraoral periapical radiograph (IOPAR)] along with an interproximal PPD equal to 5 mm and CAL more than or equal to 3mm when evaluated 8 weeks after phase I therapy [scaling and Root Planing (SRP)]
Exclusion criteria
Exclusion criteria: Patients with hematological or immunological disorders Pregnant or lactating females, Smokers or the other tobacco products users, Those taking drugs known to interfere with wound healing [Bisphosphonates, Corticosteroids] With a history of antibiotics use or periodontal therapy within past 6 months. With furcation involvement in combination with the intra-bony defect With restorations extending beyond the CEJ at the defect site With an indistinguishable CEJ either clinically or radiographically, With periapical pathology, unrestored caries, defective restorations, root resorption. With mobility classified as Miller class 2 or greater, Patients who were not willing to sign an informed consent were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure of the study will be defect fill and Crestal bone resorptionTimepoint: 6 months and 9 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will include pocket probing depth reduction and gain in clinical Attachment level and Plaque Index Timepoint: 6 months and 9 months | — |
Countries
India
Contacts
Public ContactDr Gowri Pendyala
Pravara Institute Of Medical Sciences loni
Outcome results
None listed